76 results on '"Frost, Adaani E."'
Search Results
2. Application of the REVEAL risk score calculator 2.0 in the CHEST study
3. The echocardiographic course of pretransplant pulmonary hypertension following kidney transplantation and associated outcomes
4. Optimization of Acute Kidney Injury (AKI) Time Definitions Using the Electronic Health Record: A First Step in Automating In-Hospital AKI Detection
5. Application of the REVEAL risk score calculator 2.0 in the PATENT study
6. Defining Vasoplegia Following Durable, Continuous Flow Left Ventricular Assist Device Implantation
7. United States Pulmonary Hypertension Scientific Registry
8. Transbronchial Biopsies: Clinical Perspective
9. The Association of Pretransplant Pulmonary Hypertension With Patient and Graft Survival After Kidney Transplantation: A Retrospective Cohort Study
10. Outcomes of kidney transplantation using deceased donors with history of diabetes
11. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial
12. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
13. Predicting Survival in Patients With Pulmonary Arterial Hypertension
14. United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
15. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
16. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score
17. Response
18. Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL
19. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension
20. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis
21. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation
22. Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension
23. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
24. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study
25. The Intersection of Pulmonary Hypertension and Solid Organ Transplantation
26. Navigating the Road to Transplant in Pulmonary Arterial Hypertension: A Road Less Taken
27. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension
28. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
29. Five-Year Outcomes of Patients Enrolled in the REVEAL Registry
30. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
31. Validation of two predictive models for survival in pulmonary arterial hypertension
32. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance
33. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis
34. Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
35. Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension
36. Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension
37. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension
38. Demographics and Outcomes of Patients Diagnosed With Pulmonary Hypertension With Pulmonary Capillary Wedge Pressures 16 to 18 mm Hg
39. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study)
40. An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry
41. Validation Of The French Pulmonary Hypertension Network Equation To Estimate Survival: A REVEAL Analysis
42. Can Pulmonary Arterial Hypertension Be Diagnosed by an Elevated Pulmonary Capillary Wedge Pressure Outside of the Guideline Criteria?: Response
43. Delay in Recognition of Pulmonary Arterial Hypertension
44. The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States
45. REVEAL Registry: Impact of Clinical Worsening on Three-Year Outcomes in Pulmonary Arterial Hypertension
46. PROGNOSTIC VALUE OF HEART RATE AND SYSTEMIC BLOOD PRESSURE IN PULMONARY ARTERIAL HYPERTENSION
47. Pulmonary Arterial Hypertension
48. Pulmonary Hypertension and Lung Transplantation, 2010
49. REVEAL REGISTRY: EFFECT OF HISTORY OF ANOREXIGEN USE ON OUTCOMES OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
50. Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.